{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:14:03Z","timestamp":1791274443695,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2012,3,21]],"date-time":"2012-03-21T00:00:00Z","timestamp":1332288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) study was a randomized, double-blind, double-dummy, active- and placebo-controlled, multiple-dose, phase 3 study to assess the efficacy and safety of oral recombinant calcitonin for treatment of postmenopausal osteoporosis. A total of 565 women age 46 to 86 (mean 66.5) years were randomized (4:3:2) to receive oral recombinant salmon calcitonin (rsCT) tablets (0.2\u2009mg\/d) plus placebo nasal spray, synthetic salmon calcitonin (ssCT) nasal spray (200 IU\/d) plus placebo tablets, or placebo (placebo tablets plus placebo nasal spray), respectively for 48 weeks. All women received calcium (\u22651000\u2009mg\/d) and vitamin D (800 IU\/d). Women randomized to oral rsCT had a mean\u2009\u00b1\u2009SD percent increase from baseline in lumbar spine bone mineral density (BMD) (1.5%\u2009\u00b1\u20093.2%) that was greater than those randomized to ssCT nasal spray (0.78%\u2009\u00b1\u20092.9%) or placebo (0.5%\u2009\u00b1\u20093.2%). Lumbar spine BMD change in those receiving nasal calcitonin did not differ from placebo. Oral rsCT treatment also resulted in greater improvements in trochanteric and total proximal femur BMD than ssCT nasal spray. Reductions in bone resorption markers with oral rsCT were greater than those observed in ssCT nasal spray or placebo recipients. Approximately 80% of subjects in each treatment group experienced an adverse event, the majority of which were mild or moderate in intensity. Gastrointestinal system adverse events were reported by nearly one-half of women in all treatment groups and were the principal reason for premature withdrawals. Less than 10% of women experienced a serious adverse event and no deaths occurred. Overall, oral rsCT was superior to nasal ssCT and placebo for increasing BMD and reducing bone turnover. Oral rsCT was safe and as well tolerated as ssCT nasal spray or placebo. Oral calcitonin may provide an additional treatment alternative for women with postmenopausal osteoporosis. \u00a9 2012 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.1602","type":"journal-article","created":{"date-parts":[[2012,3,22]],"date-time":"2012-03-22T23:14:04Z","timestamp":1332458044000},"page":"1821-1829","source":"Crossref","is-referenced-by-count":143,"title":["A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: The oral calcitonin in postmenopausal osteoporosis (ORACAL) trial"],"prefix":"10.1093","volume":"27","author":[{"given":"Neil","family":"Binkley","sequence":"first","affiliation":[{"name":"Osteoporosis Clinical Center and Research Program, University of Wisconsin, Madison, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bolognese","sequence":"additional","affiliation":[{"name":"Bethesda Health Research, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sidorowicz-Bialynicka","sequence":"additional","affiliation":[{"name":"Synexus SCM sp. z o.o., Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem","family":"Vally","sequence":"additional","affiliation":[{"name":"Synexus Clinical Research Centres SA, Pretoria, Republic of South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Trout","sequence":"additional","affiliation":[{"name":"Rutgers, The State University of New Jersey, New Brunswick, NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Miller","sequence":"additional","affiliation":[{"name":"Bioclinica, Inc., Newtown, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E","family":"Buben","sequence":"additional","affiliation":[{"name":"Tarsa Therapeutics, Inc., Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P","family":"Gilligan","sequence":"additional","affiliation":[{"name":"Tarsa Therapeutics, Inc., Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S","family":"Krause","sequence":"additional","affiliation":[{"name":"Tarsa Therapeutics, Inc., Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,3,21]]},"reference":[{"issue":"4","key":"2024020318274462300_bib1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00198-007-0490-1","article-title":"Salmon calcitonin: a review of current and future indications","volume":"19","author":"Chesnut","year":"2008","journal-title":"Osteoporos Int."},{"issue":"15","key":"2024020318274462300_bib2","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1073\/pnas.82.15.5064","article-title":"Linkage map of the short arm of human chromosome 11: location of the genes for catalase, calcitonin, and insulin-like growth factor II","volume":"82","author":"Kittur","year":"1985","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2024020318274462300_bib3","first-page":"352","volume-title":"Calcitonin 1980, Proc Int Symp, Milan","author":"N\u00fcesch","year":"1981"},{"key":"2024020318274462300_bib4","author":"Miacalin\u00ae (calcitonin-salmon) injection, synthetic [package insert]","year":"2009"},{"key":"2024020318274462300_bib5","year":"2009"},{"key":"2024020318274462300_bib6","first-page":"12","article-title":"Pharmacokinetic study with synthetic salmon calcitonin (Sandoz)","volume":"10","author":"Beveridge","year":"1976","journal-title":"Z Gastroenterol Verh."},{"issue":"5A","key":"2024020318274462300_bib7","doi-asserted-by":"crossref","first-page":"44S","DOI":"10.1016\/0002-9343(93)90382-Y","article-title":"Calcitonin for prevention and treatment of osteoporosis","volume":"95","author":"Reginster","year":"1993","journal-title":"Am J Med."},{"key":"2024020318274462300_bib8","year":"2011"},{"issue":"11","key":"2024020318274462300_bib9","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00198-006-0179-x","article-title":"Compliance with drug therapy for postmenopausal osteoporosis","volume":"17","author":"Weycker","year":"2006","journal-title":"Osteoporos Int."},{"key":"2024020318274462300_bib10","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J Bone Miner Res."},{"key":"2024020318274462300_bib11","author":"Brody","year":"2011"},{"issue":"6","key":"2024020318274462300_bib12","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/sim.1450","article-title":"Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo","volume":"22","author":"Pigeot","year":"2003","journal-title":"Stat Med."},{"issue":"5","key":"2024020318274462300_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF01623830","article-title":"Prevention of osteoporosis with nasal calcitonin: effect of anti-calcitonin antibody formation","volume":"3","author":"Reginster","year":"1993","journal-title":"Osteoporos Int."},{"key":"2024020318274462300_bib14","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality - the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N Engl J Med."},{"key":"2024020318274462300_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med."},{"key":"2024020318274462300_bib16","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s00198-004-1770-7","article-title":"Risk of fracture among women who lose bone density during treatment with alendronate","volume":"16","author":"Chapurlat","year":"2005","journal-title":"Osteoporos Int."},{"key":"2024020318274462300_bib17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res."},{"key":"2024020318274462300_bib18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.vaccine.2011.11.003","article-title":"New insights in mucosal vaccine development","volume":"30","author":"Pavot","year":"2012","journal-title":"Vaccine."},{"key":"2024020318274462300_bib19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med."},{"key":"2024020318274462300_bib20","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1359\/JBMR.050411","article-title":"Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study","volume":"20","author":"Chesnut","year":"2005","journal-title":"J Bone Miner Res."},{"key":"2024020318274462300_bib21","author":"Mehta"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.1602","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/27\/8\/1821\/56560520\/1602_ftp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/27\/8\/1821\/56560520\/1602_ftp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:46:25Z","timestamp":1710341185000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/27\/8\/1821-1829\/7598297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,21]]},"references-count":21,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2012,3,21]]},"published-print":{"date-parts":[[2012,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.1602","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,8,1]]},"published":{"date-parts":[[2012,3,21]]}}}